MiteshJBoradMD

Oncology • Phoenix, AZ

Assistant Professor of Medicine Mayo Clinic

Join to view full profile

Dr. Borad is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Borad's full profile

Already have an account?

Office
5777 E. Mayo Boulevard
Phoenix, AZ 85050
Is this information wrong?

Education & Training

Tulane UniversityFellowship, Hematology and Medical Oncology, 2003 - 2005
Cedars-Sinai Medical CenterResidency, Internal Medicine, 2000 - 2003
Rutgers New Jersey Medical SchoolClass of 2000

Certifications & Licensure

CA State Medical License 2001 - Present
AZ State Medical License 2005 - 2025
LA State Medical License 2003 - 2005
American Board of Internal Medicine Medical Oncology

Clinical Trials

Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors Start of enrollment: 2008 Aug 01
Completed
Phase 1, Phase 2
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma Start of enrollment: 2010 Jun 01
Completed
Phase 2
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors Start of enrollment: 2010 Jul 01
Completed
Phase 1
Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients Start of enrollment: 2011 Nov 01
Terminated
Phase 2
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery Start of enrollment: 2012 May 01
Completed
Phase 1
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers Start of enrollment: 2012 Feb 27
Completed
Phase 1, Phase 2
Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors Start of enrollment: 2012 Aug 03
Active, not recruiting
Phase 1
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection Start of enrollment: 2013 Apr 01
Terminated
Phase 1
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Start of enrollment: 2013 May 14
Completed
Phase 2
Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma Start of enrollment: 2014 Jun 01
Completed
Phase 1, Phase 2
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma Start of enrollment: 2014 Jul 23
Terminated
Phase 2
Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors Start of enrollment: 2015 Feb 18
Terminated
Phase 1
Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions Start of enrollment: 2014 Dec 01
Completed
Phase 2
Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Start of enrollment: 2016 Jan 01
Completed
Early Phase 1
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Start of enrollment: 2017 May 25
Terminated
Phase 1
A Study of ABC294640 (Yeliva ®) Alone and in Combination With Hydroxychloroquine Sulfate in Treatment of Patients With Advanced Cholangiocarcinoma Start of enrollment: 2018 Mar 07
Completed
Phase 2
Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer Start of enrollment: 2018 Sep 26
Active, not recruiting
Phase 2
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC Start of enrollment: 2019 Sep 20
Terminated
Phase 2, Phase 3
Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer Start of enrollment: 2019 Oct 18
Completed
Phase 2
Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors Start of enrollment: 2021 Apr 11
Recruiting
Phase 1, Phase 2
A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma Start of enrollment: 2021 Oct 20
Active, not recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

A Phase 1 Study of KIN-3248, an irreversible small molecule pan-FGFR inhibitor, in Patients with Advanced FGFR 2/3 Driven Solid Tumors.
Harding, J., Rastislav Bahleda, Cesar A Perez, Li-Tzong Chen, Do-Youn Oh, Paul Severson, Betty Y Tam, Benjamin Garmezy, Mitesh J Borad, Shumei Kato, Cheng Quah, James ...> ;Cancer Research Communications. 2024 Apr 11
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort.
Emiloju, O., Yin, J., Koubek, E., Reid, J., Borad, M., Lou, Y., Seetharam, M., Edelman, M., Sausville, E., Jiang, Y., Kaseb, A., Posey, J., Davis, S., Gores, G., Rober...> ;Investigational New Drugs. 2024 Feb 1
An overview of up-and-coming immune checkpoint inhibitors for pancreatic cancer.
Uson Junior, P., Borad, M., Babiker, H., Wang, J., Mahadevia, H.> ;Expert Opinion on Pharmacotherapy. 2024 Feb 1
APRI score is not predictive of post-surgical outcomes in cholangiocarcinoma patients.
Loveday, T., Junior, P., Aslam, F., Truty, M., Smoot, R., Bekaii-Saab, T., Stucky, C., Babiker, H., Borad, M.> ;Annals of Gastroenterology. 2023 Dec 20
Genome-Wide Association Study of Gallstone Disease Identifies Novel Candidate Genomic Variants in a Latino Community of Southwest USA.
Amit Arora, Khadijah Jack, Ashok V Kumar, Mitesh Borad, Marlene E Girardo, Eleanna De Filippis, Ping Yang, Valentin Dinu> ;Journal of Racial and Ethnic Health Disparities. 2023 Nov 28
Chimerization of the Anti-Viral CD8T Cell Response with A Broad Anti-Tumor T Cell Response Reverses Inhibition of Checkpoint Blockade Therapy by Oncolytic Virotherapy.
Vile, R., Webb, M., van Vloten, J., Evgin, L., Sangsuwannukul, T., Kendall, B., Tonne, J., Thompson, J., Metko, M., Moore, M., Yerovi, M., McNiven, M., Monga, S., Robe...> ;Research Square. 2023 Nov 20
1 citations
Targetingin pancreatic adenocarcinoma: Progress in demystifying the holy grail.
Ahmed Elhariri, Ahmed Alhaj, Daniel Ahn, Mohamad Bassam Sonbol, Tanios Bekaii-Saab, Christina Wu, Michael Scott Rutenberg, John Stauffer, Jason Starr, Umair Majeed, Je...> ;World Journal of Clinical Oncology. 2023 Aug 24
The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma.
Leontios Pappas, Islam Baiev, Stephanie Reyes, Andrea Grace Bocobo, Apurva Jain, Kristen Spencer, Tri Minh Le, Osama E Rahma, Jordan Maurer, Jen Stanton, Karen Zhang, ...> ;JCO Precision Oncology. 2023 Aug 1
15 citations
NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023.
Al B Benson, Michael I D'Angelica, Thomas Abrams, Daniel E Abbott, Aijaz Ahmed, Daniel A Anaya, Robert Anders, Chandrakanth Are, Melinda Bachini, David Binder, Mitesh ...> ;Journal of the National Comprehensive Cancer Network. 2023 Jul 1
2 citations
Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
Milind Javle, Gentry King, Kristen Spencer, Mitesh J Borad> ;The Oncologist. 2023 Nov 2
A drug safety evaluation of pemigatinib for advanced cholangiocarcinoma.
Pedro Luiz Serrano Uson, Jeremiah Bearss, Hani M Babiker, Mitesh Borad> ;Expert Opinion on Drug Safety. 2023 Jun 26
Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma.
Sri Harsha Tella, Nathan Foster, Shi Qian, Tran Nguyen, Mitesh J Borad, Robert R McWilliams, Steven R Alberts, Wen Wee Ma, Sakti Chakrabarti, Briant Fruth, Jaclynn Wes...> ;The Oncologist. 2023 Oct 3
Multi-modal efficacy of a chimeric vesiculovirus expressing the Morreton glycoprotein in sarcoma.
Chelsae R Watters, Oumar Barro, Natalie M Elliott, Yumei Zhou, Musa Gabere, Elizabeth Raupach, Alexander T Baker, Michael T Barrett, Kenneth H Buetow, Bertram Jacobs, ...> ;Molecular Therapy Oncolytics. 2023 Jun 15
1 citations
Trap and ambush therapy using sequential primary and tumor escape-selective oncolytic viruses.
Mason J Webb, Timothy Kottke, Benjamin L Kendall, Jack Swanson, Chisom Uzendu, Jason Tonne, Jill Thompson, Muriel Metko, Madelyn Moore, Mitesh Borad, Lewis Roberts, Ro...> ;Molecular Therapy Oncolytics. 2023 Jun 15
Dynamics and survival associations of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapy.
Aakash P Desai, Farhad Kosari, Maria Disselhorst, Jun Yin, Alireza Agahi, Tobias Peikert, Julia Udell, Sarah H Johnson, James Smadbeck, Stephen Murphy, Giannoula Karag...> ;Journal for Immunotherapy of Cancer. 2023 Jun 1
Targeting leukemia inhibitory factor in pancreatic adenocarcinoma.
Jing Wang, Christian Karime, Umair Majeed, Jason S Starr, Mitesh J Borad, Hani M Babiker> ;Expert Opinion on Investigational Drugs. 2023 May 1
1 citations
CS-iCCA, A New Clinically Based Staging System for Intrahepatic Cholangiocarcinoma: Establishment and External Validation.
Maria E Lozada, Ning Zhang, Weidong Jin, Nicha Wongjarupong, Ju Dong Yang, Molly M Voss, Kritika Prasai, Dominic O Amakye, William S Harmsen, Sushant Chaudhary, Oliver...> ;The American Journal of Gastroenterology. 2023 Dec 1
3 citations
Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma.
Kristen Spencer, Leontios Pappas, Islam Baiev, Jordan Maurer, Andrea Grace Bocobo, Karen Zhang, Apurva Jain, Anaemy Danner De Armas, Stephanie Reyes, Tri Minh Le, Osam...> ;Journal of the National Cancer Institute. 2023 Jul 6
6 citations
Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers.
Changhoon Yoo, Milind M Javle, Helena Verdaguer Mata, Filippo de Braud, Jörg Trojan, Jean-Luc Raoul, Jin Won Kim, Makoto Ueno, Choong-Kun Lee, Susumu Hijioka, Antonio ...> ;Hepatology. 2023 Sep 1
Targeting Fibroblast Growth Factor Receptor Pathway: Precision Medicine for Biliary Cancer and Beyond.
Pedro Luiz Serrano Uson Junior, Mitesh J Borad> ;Seminars in Liver Disease. 2023 May 1
Epigenomics may begin to explaindifferential response to hypomethylating agents in MMR-D hypermethylated endometrial cancer.
El Khoury, L., Lin, W., Smadbeck, J., Barrett, M., Sadeghian, D., McCune, A., Karagouga, G., Cheville, J., Harris, F., Kinsella, L., Feathers, R., Schafer Klein, J., W...> ;Epigenomics. 2023 Mar 1
8 citations
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance.
Diego F Calvisi, Luke Boulter, Javier Vaquero, Anna Saborowski, Luca Fabris, Pedro M Rodrigues, Cédric Coulouarn, Rui E Castro, Oreste Segatto, Chiara Raggi, Luc J W v...> ;Nature Reviews. Gastroenterology & Hepatology. 2023 Jul 1
10 citations
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.
James J Harding, Sarina A Piha-Paul, Ronak H Shah, Jessica J Murphy, James M Cleary, Geoffrey I Shapiro, David I Quinn, Irene Braña, Victor Moreno, Mitesh Borad, Shere...> ;Nature Communications. 2023 Feb 6
1 citations
Novel precision therapies for cholangiocarcinoma: an overview of clinical trials.
Pedro Luiz Serrano Uson Junior, Jeremiah Bearss, Hani M Babiker, Mitesh J Borad> ;Expert Opinion on Investigational Drugs. 2023 Jan 1
9 citations
Genome-wide analysis of aberrant position and sequence of plasma DNA fragment ends in patients with cancer.
Karan K Budhraja, Bradon R McDonald, Michelle D Stephens, Tania Contente-Cuomo, Havell Markus, Maria Farooq, Patricia F Favaro, Sydney Connor, Sara A Byron, Jan B Egan...> ;Science Translational Medicine. 2023 Jan 11
Join now to see all

Journal Articles

Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma
Mohamad Bassam Sonbol, Amit Mahipal, Zhaohui Jin, Kabir Mody, Mitesh J Borad, Daniel H Ahn, Tanios Bekaii-Saab, JAMA Oncology
E6201, an Intravenous MEK1 Inhibitor, Achieves an Exceptional Response in BRAF V600E-Mutated Metastatic Malignant Melanoma with Brain Metastases
Mitesh J Borad, Raoul Tibes, Michael S Gordon, Ronald L Korn, Investigational New Drugs
Chromoanasynthesis Is a Common Mechanism That Leads to ERBB2 Amplifications in a Cohort of Early Stage HER2+ Breast Cancer Samples
Katherine B Geiersbach, Mitesh J Borad, Sarah A McLaughlin, BioMed Central

Lectures

A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) chol...
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
Clinical Hematology and Oncology 2013: The 10th Annual Mayo Board Review
Mayo School of Continuous Professional Development, Scottsdale, Arizona - 1/18/2013